相关参考文献
注意：仅列出部分参考文献，下载原文获取全部文献信息。OA04.05 Trastuzumab Deruxtecan in HER2-Overexpressing Metastatic Non-Small Cell Lung Cancer: Interim Results of DESTINY-Lung01
K. Nakagawa et al.
Journal of Thoracic Oncology (2021)
Pyrotinib in HER2-Mutant Advanced Lung Adenocarcinoma After Platinum-Based Chemotherapy: A Multicenter, Open-Label, Single-Arm, Phase II Study
Caicun Zhou et al.
JOURNAL OF CLINICAL ONCOLOGY (2020)
FDA- and EMA-Approved Tyrosine Kinase Inhibitors in Advanced EGFR-Mutated Non-Small Cell Lung Cancer: Safety, Tolerability, Plasma Concentration Monitoring, and Management
Isabelle Solassol et al.
BIOMOLECULES (2019)
Ado-Trastuzumab Emtansine for Patients With HER2-Mutant Lung Cancers: Results From a Phase II Basket Trial
Bob T. Li et al.
JOURNAL OF CLINICAL ONCOLOGY (2018)
A Phase II Trial of Poziotinib in EGFR and HER2 exon 20 Mutant Non-Small Cell Lung Cancer (NSCLC)
J. Heymach et al.
JOURNAL OF THORACIC ONCOLOGY (2018)
HER2 Amplification and HER2 Mutation Are Distinct Molecular Targets in Lung Cancers
Bob T. Li et al.
JOURNAL OF THORACIC ONCOLOGY (2016)
HER2 gene mutations in non-small cell lung carcinomas: Concurrence with her2 gene amplification and her2 protein expression and phosphorylation
Mikiko Suzuki et al.
LUNG CANCER (2015)
HER2 status in lung adenocarcinoma: A comparison of immunohistochemistry, fluorescence in situ hybridization (FISH), dual-ISH, and gene mutations
Akihiko Yoshizawa et al.
LUNG CANCER (2014)
Comprehensive molecular profiling of lung adenocarcinoma
Eric A. Collisson et al.
NATURE (2014)
Non-small-cell lung cancers: a heterogeneous set of diseases
Zhao Chen et al.
NATURE REVIEWS CANCER (2014)
Lung Cancer That Harbors an HER2 Mutation: Epidemiologic Characteristics and Therapeutic Perspectives
Julien Mazieres et al.
JOURNAL OF CLINICAL ONCOLOGY (2013)
The quest to overcome resistance to EGFR-targeted therapies in cancer
Curtis R. Chong et al.
NATURE MEDICINE (2013)
Prevalence, Clinicopathologic Associations, and Molecular Spectrum of ERBB2 (HER2) Tyrosine Kinase Mutations in Lung Adenocarcinomas
Maria E. Arcila et al.
CLINICAL CANCER RESEARCH (2012)
Lung Adenocarcinomas with HER2-Activating Mutations Are Associated with Distinct Clinical Features and HER2/EGFR Copy Number Gains
Chenguang Li et al.
JOURNAL OF THORACIC ONCOLOGY (2012)
Randomized Phase II Multicenter Trial of Two Schedules of Lapatinib as First- or Second-Line Monotherapy in Patients with Advanced or Metastatic Non-Small Cell Lung Cancer
Helen J. Ross et al.
CLINICAL CANCER RESEARCH (2010)
Novel anticancer targets: revisiting ERBB2 and discovering ERBB3
Jose Baselga et al.
NATURE REVIEWS CANCER (2009)
EGFR point mutation in non-small cell lung cancer is occasionally accompanied by a second mutation or amplification
Toshihiko Yokoyama et al.
CANCER SCIENCE (2006)
Increased HER2 gene copy number is associated with response to gefitinib therapy in epidermal growth factor receptor-positive non-small-cell lung cancer patients
F Cappuzzo et al.
JOURNAL OF CLINICAL ONCOLOGY (2005)
Combination treatment with erlotinib and pertuzumab against human tumor xenografts is superior to monotherapy
T Friess et al.
CLINICAL CANCER RESEARCH (2005)
Trastuzumab in the treatment of advanced non-small-cell lung cancer: Is there a role? Focus on eastern cooperative oncology group study 2598
CJ Langer et al.
JOURNAL OF CLINICAL ONCOLOGY (2004)
HER-2/neu protein expression and gene alteration in stage I-IIIA non-small-cell lung cancer: A study of 140 cases using a combination of high throughput tissue microarray, immunohistochemistry, and fluorescent in situ hybridization
DF Tan et al.
DIAGNOSTIC MOLECULAR PATHOLOGY (2003)
Evaluation of HER-2/neu gene amplification and protein expression in non-small cell lung carcinomas
FR Hirsch et al.
BRITISH JOURNAL OF CANCER (2002)
分享论文
